Skip to main content

Advertisement

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Article metrics

  • 187 Accesses

The original article was published in Biomarker Research 2019 7:19

Correction to: Biomark Res (2019) 7:19

https://doi.org/10.1186/s40364-019-0170-2

The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoxantrone, etoposide, cyclophosphamide’.

It should instead be stated that MEC stands for ‘mitoxantrone, etoposide, cytarabine’.

Reference

  1. 1.

    Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. https://doi.org/10.1186/s40364-019-0170-2.

Download references

Author information

Correspondence to Yongping Song or Delong Liu.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, J., Song, Y. & Liu, D. Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res 7, 21 (2019) doi:10.1186/s40364-019-0172-0

Download citation